Skip to content

ANI Pharmaceuticals

US · ANIP #2919 by market cap Listed 1970
71.93 +0.41 +0.57%
Live - 5344 symbols - heartbeat 108s ago · 2026-10-08 08:07
Pre-market 71.99 +0.08%
After-hours 72.15 +0.31%
Market cap
1.65B
P/B
2.77
EPS
3.32
Reader sentiment Are you bullish or bearish on ANIP?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Truist Financial Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating
    Market Newswire · 2026/5/11
  • Rating change
    J.P. Morgan Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $115
    Market Newswire · 2026/8/10
  • Barclays Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/8/26
  • H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $121
    Market Newswire · 2026/9/22
  • Leerink Partners Initiates ANI Pharmaceuticals(ANIP.US) With Buy Rating, Announces Target Price $104
    Market Newswire · 2026/9/9
  • Rating change
    Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $115
    Market Newswire · 2025/11/10
  • Rating change
    Truist Financial Downgrades ANI Pharmaceuticals(ANIP.US) to Hold Rating
    Market Newswire · 2025/11/10
  • Rating change
    CCORF Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating, Maintains Target Price $91
    Market Newswire · 2026/7/17
  • Rating change
    J.P. Morgan Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $115
    Market Newswire · 2025/9/24
  • Rating change
    Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $115
    Market Newswire · 2026/1/13
  • Rating change
    Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $124
    Market Newswire · 2026/7/14
  • Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Cuts Target Price to $119
    Market Newswire · 2026/8/10
  • CCORF Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating, Cuts Target Price to $90
    Market Newswire · 2026/8/10
  • Rating change
    Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $114
    Market Newswire · 2025/10/28
  • Rating change
    Piper Sandler Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $111
    Market Newswire · 2026/4/23
  • Rating change
    Leerink Partners Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $103
    Market Newswire · 2025/10/15
  • Rating change
    CCORF Downgrades ANI Pharmaceuticals(ANIP.US) to Hold Rating, Raises Target Price to $91
    Market Newswire · 2026/7/17
  • Rating change
    Jefferies Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $120
    Market Newswire · 2026/3/25
  • Rating change
    Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $124
    Market Newswire · 2026/1/16
  • Rating change
    H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $121
    Market Newswire · 2025/9/17

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:07:21 · For reference only, not investment advice and not tailored to your situation.